Catch and Release: How Do Kinetochores Hook the Right Microtubules During Mitosis?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
RASSF1A Interacts with and Activates the Mitotic Kinase Aurora-A
Oncogene (2008) 27, 6175–6186 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $32.00 www.nature.com/onc ORIGINAL ARTICLE RASSF1A interacts with and activates the mitotic kinase Aurora-A L Liu1, C Guo1, R Dammann2, S Tommasi1 and GP Pfeifer1 1Division of Biology, Beckman Research Institute, City of Hope Cancer Center, Duarte, CA, USA and 2Institute of Genetics, University of Giessen, Giessen, Germany The RAS association domain family 1A (RASSF1A) gene tumorigenesis and carcinogen-induced tumorigenesis is located at chromosome 3p21.3 within a specific area of (Tommasi et al., 2005; van der Weyden et al., 2005), common heterozygous and homozygous deletions. RASS- supporting the notion that RASSF1A is a bona fide F1A frequently undergoes promoter methylation-asso- tumor suppressor. However, it is not fully understood ciated inactivation in human cancers. Rassf1aÀ/À mice how RASSF1A is involved in tumor suppression. are prone to both spontaneous and carcinogen-induced The biochemical function of the RASSF1A protein is tumorigenesis, supporting the notion that RASSF1A is a largely unknown. The homology of RASSF1A with the tumor suppressor. However, it is not fully understood how mammalian Ras effector novel Ras effector (NORE)1 RASSF1A is involved in tumor suppression pathways. suggests that the RASSF1A gene product may function Here we show that overexpression of RASSF1A inhibits in signal transduction pathways involving Ras-like centrosome separation. RASSF1A interacts with Aurora-A, proteins. However, recent data indicate that RASSF1A a mitotic kinase. Surprisingly, knockdown of RASS- itself binds to RAS only weakly and that binding to F1A by siRNA led to reduced activation of Aurora-A, RAS may require heterodimerization of RASSF1A and whereas overexpression of RASSF1A resulted in in- NORE1 (Ortiz-Vega et al., 2002). -
HIPK2 and Extrachromosomal Histone H2B Are Separately Recruited by Aurora-B for Cytokinesis
Oncogene https://doi.org/10.1038/s41388-018-0191-6 ARTICLE HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis 1 1 2 3 2 Laura Monteonofrio ● Davide Valente ● Manuela Ferrara ● Serena Camerini ● Roberta Miscione ● 3 1,2 1 Marco Crescenzi ● Cinzia Rinaldo ● Silvia Soddu Received: 14 November 2017 / Revised: 24 January 2018 / Accepted: 5 February 2018 © The Author(s) 2018. This article is published with open access Abstract Cytokinesis, the final phase of cell division, is necessary to form two distinct daughter cells with correct distribution of genomic and cytoplasmic materials. Its failure provokes genetically unstable states, such as tetraploidization and polyploidization, which can contribute to tumorigenesis. Aurora-B kinase controls multiple cytokinetic events, from chromosome condensation to abscission when the midbody is severed. We have previously shown that HIPK2, a kinase involved in DNA damage response and development, localizes at the midbody and contributes to abscission by phosphorylating extrachromosomal histone H2B at Ser14. Of relevance, HIPK2-defective cells do not phosphorylate H2B 1234567890();,: and do not successfully complete cytokinesis leading to accumulation of binucleated cells, chromosomal instability, and increased tumorigenicity. However, how HIPK2 and H2B are recruited to the midbody during cytokinesis is still unknown. Here, we show that regardless of their direct (H2B) and indirect (HIPK2) binding of chromosomal DNA, both H2B and HIPK2 localize at the midbody independently of nucleic acids. Instead, by using mitotic kinase-specific inhibitors in a spatio-temporal regulated manner, we found that Aurora-B kinase activity is required to recruit both HIPK2 and H2B to the midbody. -
Stability of Heterogeneous Parallel-Bond Adhesion Clusters Under Static Load
Stability of heterogeneous parallel-bond adhesion clusters under static load Anil K. Dasanna, Gerhard Gompper, and Dmitry A. Fedosov∗ Theoretical Physics of Living Matter, Institute of Biological Information Processing and Institute for Advanced Simulation, Forschungszentrum Jülich, 52425 Jülich, Germany Adhesion interactions mediated by multiple bond types are relevant for many biological and soft matter systems, including the adhesion of biological cells and functionalized colloidal particles to various substrates. To elucidate advantages and disadvantages of multiple bond populations for the stability of heterogeneous adhesion clusters of receptor-ligand pairs, a theoretical model for a homogeneous parallel adhesion bond cluster under constant loading is extended to several bond types. The stability of the entire cluster can be tuned by changing densities of different bond populations as well as their extensional rigidity and binding properties. In particular, bond extensional rigidities determine the distribution of total load to be shared between different sub- populations. Under a gradual increase of the total load, the rupture of a heterogeneous adhesion cluster can be thought of as a multistep discrete process, in which one of the bond sub-populations ruptures first, followed by similar rupture steps of other sub-populations or by immediate detachment of the remaining cluster. This rupture behavior is qualitatively independent of involved bond types, such as slip and catch bonds. Interestingly, an optimal stability is generally achieved when the total cluster load is shared such that loads on distinct bond populations are equal to their individual critical rupture forces. We also show that cluster heterogeneity can drastically affect cluster lifetime. I. INTRODUCTION they act synergistically [28], the exact roles of different receptor-ligand pairs remain largely unknown. -
The Aurora B Kinase Activity Is Required for the Maintenance of the Differentiated State of Murine Myoblasts
Cell Death and Differentiation (2009) 16, 321–330 & 2009 Macmillan Publishers Limited All rights reserved 1350-9047/09 $32.00 www.nature.com/cdd The Aurora B kinase activity is required for the maintenance of the differentiated state of murine myoblasts G Amabile1,2, AM D’Alise1, M Iovino1, P Jones3, S Santaguida4, A Musacchio4, S Taylor5 and R Cortese*,1 Reversine is a synthetic molecule capable of inducing dedifferentiation of C2C12, a murine myoblast cell line, into multipotent progenitor cells, which can be redirected to differentiate in nonmuscle cell types under appropriate conditions. Reversine is also a potent inhibitor of Aurora B, a protein kinase required for mitotic chromosome segregation, spindle checkpoint function, cytokinesis and histone H3 phosphorylation, raising the possibility that the dedifferentiation capability of reversine is mediated through the inhibition of Aurora B. Indeed, here we show that several other well-characterized Aurora B inhibitors are capable of dedifferentiating C2C12 myoblasts. Significantly, expressing drug-resistant Aurora B mutants, which are insensitive to reversine block the dedifferentiation process, indicating that Aurora B kinase activity is required to maintain the differentiated state. We show that the inhibition of the spindle checkpoint or cytokinesis per se is not sufficient for dedifferentiation. Rather, our data support a model whereby changes in histone H3 phosphorylation result in chromatin remodeling, which in turn restores the multipotent state. Cell Death and Differentiation (2009) 16, 321–330; doi:10.1038/cdd.2008.156; published online 31 October 2008 Lineage-restricted cells can be reprogramed to a state Evidence is emerging that the role of Aurora B is not of pluripotency by several different manipulations, including restricted to mitosis and cell division. -
Discovery of BPR1K871, a Quinazoline Based
www.impactjournals.com/oncotarget/ Oncotarget, 2016, Vol. 7, (No. 52), pp: 86239-86256 Research Paper Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation Yung Chang Hsu1,*, Mohane Selvaraj Coumar2,*, Wen-Chieh Wang1,*, Hui-Yi Shiao1,*, Yi-Yu Ke1, Wen-Hsing Lin1, Ching-Chuan Kuo1, Chun-Wei Chang1, Fu-Ming Kuo1, Pei-Yi Chen1, Sing-Yi Wang1, An-Siou Li1, Chun-Hwa Chen1, Po-Chu Kuo1, Ching- Ping Chen1, Ming-Hsine Wu1, Chen-Lung Huang1, Kuei-Jung Yen1, Yun-I Chang1, John T.-A. Hsu1, Chiung-Tong Chen1, Teng-Kuang Yeh1, Jen-Shin Song1, Chuan Shih1, Hsing-Pang Hsieh1,3 1Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan, ROC 2Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry, India 3Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan, ROC *These authors contributed equally to this work Correspondence to: Hsing-Pang Hsieh, email: [email protected] Keywords: acute myeloid leukemia, aurora kinase, FLT3, quinazoline, multi-kinase inhibitor Received: July 25, 2016 Accepted: November 07, 2016 Published: November 15, 2016 ABSTRACT The design and synthesis of a quinazoline-based, multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and other malignancies is reported. Based on the previously reported furanopyrimidine 3, quinazoline core containing lead 4 was synthesized and found to impart dual FLT3/AURKA inhibition (IC50 = 127/5 nM), as well as improved physicochemical properties. A detailed structure-activity relationship study of the lead 4 allowed FLT3 and AURKA inhibition to be finely tuned, resulting in AURKA selective (5 and 7; 100-fold selective over FLT3), FLT3 selective (13; 30-fold selective over AURKA) and dual FLT3/AURKA selective (BPR1K871; IC50 = 19/22 nM) agents. -
Kinase-Targeted Cancer Therapies: Progress, Challenges and Future Directions Khushwant S
Bhullar et al. Molecular Cancer (2018) 17:48 https://doi.org/10.1186/s12943-018-0804-2 REVIEW Open Access Kinase-targeted cancer therapies: progress, challenges and future directions Khushwant S. Bhullar1, Naiara Orrego Lagarón2, Eileen M. McGowan3, Indu Parmar4, Amitabh Jha5, Basil P. Hubbard1 and H. P. Vasantha Rupasinghe6,7* Abstract The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein- coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150 kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug development. Nevertheless, many factors confound the clinical efficacy of these molecules. Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics determine how useful a compound will be in the treatment of a given cancer. This review provides an overview of kinase-targeted drug discovery and development in relation to oncology and highlights the challenges and future potential for kinase-targeted cancer therapies. Keywords: Kinases, Kinase inhibition, Small-molecule drugs, Cancer, Oncology Background Recent advances in our understanding of the fundamen- Kinases are enzymes that transfer a phosphate group to a tal molecular mechanisms underlying cancer cell signaling protein while phosphatases remove a phosphate group have elucidated a crucial role for kinases in the carcino- from protein. -
Epigenetic Regulation of Neurogenesis by Citron Kinase Matthew Irg Genti University of Connecticut - Storrs, [email protected]
University of Connecticut OpenCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 12-10-2015 Epigenetic Regulation of Neurogenesis By Citron Kinase Matthew irG genti University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/dissertations Recommended Citation Girgenti, Matthew, "Epigenetic Regulation of Neurogenesis By Citron Kinase" (2015). Doctoral Dissertations. 933. https://opencommons.uconn.edu/dissertations/933 Epigenetic Regulation Of Neurogenesis By Citron Kinase Matthew J. Girgenti, Ph.D. University of Connecticut, 2015 Patterns of neural progenitor division are controlled by a combination of asymmetries in cell division, extracellular signals, and changes in gene expression programs. In a screen for proteins that complex with citron kinase (CitK), a protein essential to cell division in developing brain, I identified the histone methyltransferase- euchromatic histone-lysine N-methyltransferse 2 (G9a). CitK is present in the nucleus and binds to positions in the genome clustered around transcription start sites of genes involved in neuronal development and differentiation. CitK and G9a co-occupy these genomic positions in S/G2-phase of the cell cycle in rat neural progenitors, and CitK functions with G9a to repress gene expression in several developmentally important genes including CDKN1a, H2afz, and Pou3f2/Brn2. The study indicates a novel function for citron kinase in gene repression, and contributes additional evidence to the hypothesis that mechanisms that coordinate gene expression states are directly linked to mechanisms that regulate cell division in the developing nervous system. Epigenetic Regulation Of Neurogenesis By Citron Kinase Matthew J. Girgenti B.S., Fairfield University, 2002 M.S., Southern Connecticut State University, 2004 A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy at the University of Connecticut 2015 ii Copyright by Matthew J. -
Jadomycin B, an Aurora-B Kinase Inhibitor Discovered Through Virtual Screening
2386 Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening Da-Hua Fu,1 Wei Jiang,1 Jian-Ting Zheng,2 Jadomycin B is a new Aurora-B kinase inhibitor worthy of Gui-Yu Zhao,1 Yan Li,1 Hong Yi,1 Zhuo-Rong Li,1 further investigation. [Mol Cancer Ther 2008;7(8):2386–93] Jian-Dong Jiang,1 Ke-Qian Yang,2 Yanchang Wang,3 and Shu-Yi Si1 Introduction In mammals, there are three Aurora kinases, Aurora-A, B, 1Institute of Medicinal Biotechnology, Peking Union Medical College & Chinese Academy of Medical Sciences, and 2Institute and C, which display >60% sequence identity (1). Although of Microbiology, Chinese Academy of Sciences, Beijing, China; the catalytic domains of the three kinases are highly and 3Department of Biomedical Sciences, College of Medicine, conserved, they show distinct subcellular localization and Florida State University, Tallahassee, Florida biological function (2, 3). Aurora-A, which is required for centrosome maturation and separation, localizes to centro- somes from early S phase to late M phase (4). Aurora-B is a Abstract component of chromosomal passenger complex, whose Aurora kinases have emerged as promising targets for function in mitosis has been extensively studied. In cancer therapy because of their critical role in mitosis. addition to Aurora-B, the chromosomal passenger complex These kinases are well-conserved in all eukaryotes, and contains Survivin, Borealin, and inner centromere protein IPL1 gene encodes the single Aurora kinase in budding (5–7). The chromosomal passenger complex associates yeast. In a virtual screening attempt, 22 compounds were with centromeric regions of chromosomes in the early identified from nearly 15,000 microbial natural products as stages of mitosis, but it translocates to microtubules after potential small-molecular inhibitors of human Aurora-B the onset of anaphase. -
Dual PDK1/Aurora Kinase a Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation
cancers Article Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation 1, 1, 2 3 3 Ilaria Casari y, Alice Domenichini y, Simona Sestito , Emily Capone , Gianluca Sala , Simona Rapposelli 2 and Marco Falasca 1,* 1 Metabolic Signalling Group, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Australia; [email protected] (I.C.); [email protected] (A.D.) 2 Department of Pharmacy, University of Pisa, Via Bonanno, 6, 56126 Pisa, Italy; [email protected] (S.S.); [email protected] (S.R.) 3 Dipartimento di Scienze Mediche, Orali e Biotecnologiche, University “G. d’Annunzio” di Chieti-Pescara, Center for Advanced Studies and Technology (CAST), 66100 Chieti, Italy; [email protected] (E.C.); [email protected] (G.S.) * Correspondence: [email protected]; Tel.: +61-8-92669712 These authors contributed equally to this work. y Received: 8 October 2019; Accepted: 28 October 2019; Published: 31 October 2019 Abstract: Deregulation of different intracellular signaling pathways is a common feature in cancer. Numerous studies indicate that persistent activation of the phosphoinositide 3-kinase (PI3K) pathway is often observed in cancer cells. 3-phosphoinositide dependent protein kinase-1 (PDK1), a transducer protein that functions downstream of PI3K, is responsible for the regulation of cell proliferation and migration and it also has been found to play a key role in different cancers, pancreatic and breast cancer amongst others. As PI3K is being described to be aberrantly expressed in several cancer types, designing inhibitors targeting various downstream molecules of PI3K has been the focus of anticancer agent development for a long time. -
Biophysics of Selectin-Ligand Interactions in Inflammation and Cancer
Home Search Collections Journals About Contact us My IOPscience Biophysics of selectin–ligand interactions in inflammation and cancer This article has been downloaded from IOPscience. Please scroll down to see the full text article. 2011 Phys. Biol. 8 015013 (http://iopscience.iop.org/1478-3975/8/1/015013) View the table of contents for this issue, or go to the journal homepage for more Download details: IP Address: 128.220.16.163 The article was downloaded on 02/05/2013 at 00:02 Please note that terms and conditions apply. IOP PUBLISHING PHYSICAL BIOLOGY Phys. Biol. 8 (2011) 015013 (14pp) doi:10.1088/1478-3975/8/1/015013 Biophysics of selectin–ligand interactions in inflammation and cancer Luthur Siu-Lun Cheung1,4, Phrabha S Raman1,4, Eric M Balzer1,2,3, Denis Wirtz1,2,3 and Konstantinos Konstantopoulos1,2,3,5 1 Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD 21218, USA 2 NCI PS-OC Johns Hopkins Engineering in Oncology Center, The Johns Hopkins University, Baltimore, MD 21218, USA 3 Institute for NanoBioTechnology, The Johns Hopkins University, Baltimore, MD 21218, USA E-mail: [email protected] Received 21 September 2010 Accepted for publication 15 November 2010 Published 7 February 2011 Online at stacks.iop.org/PhysBio/8/015013 Abstract Selectins (L-, E- and P-selectin) are calcium-dependent transmembrane glycoproteins that are expressed on the surface of circulating leukocytes, activated platelets, and inflamed endothelial cells. Selectins bind predominantly to sialofucosylated glycoproteins and glycolipids (E-selectin only) present on the surface of apposing cells, and mediate transient adhesive interactions pertinent to inflammation and cancer metastasis. -
Theoretical Aspects of the Biological Catch Bond OLEG V
Theoretical Aspects of the Biological Catch Bond OLEG V. PREZHDO* AND YURIY V. PEREVERZEV Department of Chemistry, University of Washington, Seattle, Washington 98195 RECEIVED ON SEPTEMBER 17, 2008 CON SPECTUS he biological catch bond is fascinating and counterintuitive. When an external force is applied to a catch bond, either in vivo Tor in vitro, the bond resists breaking and becomes stronger instead. In contrast, ordinary slip bonds, which represent the vast majority of biological and chemical bonds, dissociate faster when subjected to a force. Catch-bond behavior was first predicted theoretically 20 years ago and has recently been experimentally observed in a number of protein receptor-ligand complexes. In this Account, we review the simplest physical-chemical models that lead to analytic expressions for bond lifetime, the concise uni- versal representations of experimental data, and the explicit requirements for catch binding. The phenomenon has many manifestations: increased lifetime with growing constant force is its defining characteristic. If force increases with time, as in jump-ramp experiments, catch binding creates an additional maximum in the probability density of bond rupture force. The new maximum occurs at smaller forces than the slip-binding maximum, merging with the latter at a certain ramp rate in a process resembling a phase transition. If force is applied periodically, as in blood flows, catch-bond properties strongly depend on force frequency. Catch binding results from a complex landscape of receptor-ligand interactions. Bond lifetime can increase if force (i) pre- vents dissociation through the native pathway and drives the system over a higher energy barrier or (ii) alters protein conforma- tions in a way that strengthens receptor-ligand binding. -
CHK2 Is Negatively Regulated by Protein Phosphatase 2A
University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School 5-31-2010 CHK2 is Negatively Regulated by Protein Phosphatase 2A Alyson Freeman University of South Florida Follow this and additional works at: https://scholarcommons.usf.edu/etd Part of the American Studies Commons, and the Biology Commons Scholar Commons Citation Freeman, Alyson, "CHK2 is Negatively Regulated by Protein Phosphatase 2A" (2010). Graduate Theses and Dissertations. https://scholarcommons.usf.edu/etd/3443 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. CHK2 is Negatively Regulated by Protein Phosphatase 2A by Alyson K. Freeman A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Cancer Biology College of Arts and Sciences University of South Florida Major Professor: Alvaro N. A. Monteiro, Ph.D. Gary W. Litman, Ph.D. Gary W. Reuther, Ph.D. Kenneth L. Wright, Ph.D. Date of Approval: January 14, 2010 Keywords: DNA damage response, phosphorylation, kinase, ionizing radiation, DNA double-strand break © Copyright 2010, Alyson K. Freeman DEDICATION To my husband Scott N. Freeman, my parents James P. and Carolyn C. Fay, and my sister Erin M. Fay. ACKNOWLEDGEMENTS I first and foremost would like to thank my mentor, Dr. Alvaro Monteiro. I could not have asked for a better experience in graduate school and I am grateful for all that I have learned from him.